VYNE THERAPEUTICS VYNE 深 沪
等待开盘 12-18 09:30:00 美东时间
0.6256
+0.223
+55.35%
华盛通- 最 高0.75
- 今 开0.70
- 成交量 2.49亿股
- 最 低 0.5611
- 昨 收 0.4027
- 总市值 2082.40万
- 52周最高 4.30
- 市盈率 静 --
- 换手率 747.35%
- 52周最低 0.2805
- 委 比 50.00%
- 总股本 3328.64万
- 历史最高 2869.92
- 量 比 177.21
- 振 幅 46.91%
- 历史最低 0.2805
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Agape ATP (NASDAQ:ATPC) stock rose 68.1% to $0.15 during Wednesday's r...
今天 01:06
VYNE Therapeutics shares are trading higher after the company announced it entered into a definitive merger agreement pursuant to combine with Yarrow Bioscience.
VYNE Therapeutics shares are trading higher after the company announced it ente...
12-17 21:32
VYNE Therapeutics Q3 EPS $(0.17) Misses $(0.13) Estimate, Sales $169.000K Beat $100.000K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 41.38 percent increase over losses of $(0.29) per share
11-06 21:29
VYNE Therapeutics Faces Nasdaq Non-Compliance Notice
VYNE Therapeutics ( ($VYNE) ) has shared an update. On September 11, 2025, VYNE...
09-13 04:36
VYNE Therapeutics Directors Resign Amid Financial Updates
An announcement from VYNE Therapeutics ( ($VYNE) ) is now available. On August ...
08-14 20:28
VYNE Therapeutics Q2 EPS $(0.13) Beats $(0.22) Estimate, Sales $69.000K Miss $150.000K Estimate
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.22) by 41.7 percent. This is a 40.91 percent increase over losses of $(0.22) per share from
08-14 20:05
HC Wainwright & Co. Downgrades VYNE Therapeutics to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades VYNE Therapeutics (NASDAQ:VYNE) from Buy to Neutral.
07-30 23:20
VYNE Therapeutics Announces Phase 2b Trial With Repibresib Gel In Nonsegmental Vitiligo Did Not Meet Primary Endpoint Or Key Secondary Endpoint of F-VASI50 And F-VASI75
Trial Did Not Meet Primary Endpoint or Key Secondary Endpoint of F-VASI50 and F-VASI75Nominally Statistically Significant Effects Observed in Key Secondary and Exploratory Endpoints of Change from Baseline in F-VASI and
07-30 20:08
VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo
VYNE Therapeutics announced Phase 2b trial results for Repibresib gel in nonsegmental vitiligo. The trial did not meet the primary endpoint of F-VASI50 or key secondary endpoint of F-VASI75. However, the highest dose (3%) showed nominal statistical significance in percent change from baseline in F-VASI (-43.6%) and T-VASI (-28.3%) scores. High vehicle effect and dropout rates impacted results. VYNE will terminate the trial's extension phase and s...
07-30 12:00
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
VYNE Therapeutics provided an update on its VYN202 program following a clinical hold by the FDA in April. The FDA lifted the hold for female patients on 0.25 mg and 0.5 mg doses in the Phase 1b psoriasis trial, while the 1 mg dose was excluded due to safety concerns. Preliminary data showed improvement in psoriasis symptoms and cytokine levels for VYN202-treated subjects. The company will not enroll new patients in the psoriasis trial and will fo...
07-02 11:45
